Antidepressants for chronic pain lack reliable effectiveness evidence Published on: 9 May 2023 Most antidepressants used for chronic pain are being prescribed with 鈥渋nsufficient鈥� evidence of their effectiveness, scientists have warned. A major investigation into medications used to manage long-term pain found that harms of many of the commonly recommended drugs have not been well studied. The Cochrane review, led by scientists from several UK universities including 缅北禁地 and Southampton, examined 176 trials consisting of nearly 30,000 patients involved in assessments which prescribed antidepressants for chronic pain. Among the drugs studied were amitriptyline, fluoxetine, citalopram, paroxetine, sertraline, and duloxetine – with only the latter showing reliable evidence for pain relief. Global problem One third of people globally are living with chronic pain, World Health Organisation data shows, with many prescribed antidepressants for relieving symptoms. Statistician Dr Gavin Stewart, review co-author from 缅北禁地, said: “Our study is one of the biggest of its kind and demonstrates the need for large-scale studies in this field. We would encourage funders to support high-quality studies into the use of antidepressants for chronic pain. “Data is often complex and nuanced but the evidence underpinning the use of these treatments is not conclusive for most of the antidepressants we studied and, therefore, current treatment options are hard to justify.” Amitriptyline is one of the most commonly prescribed antidepressants for pain management worldwide. In the last 12 months, around 10 million prescriptions were given to patients in England at the 10mg dose recommended for pain. By comparison, five million prescriptions were given at the higher doses recommended for depression. For duloxetine, three and a half million prescriptions were dispensed in England, but the recommended doses do not currently differ between conditions. The two-year Cochrane study was the largest ever assessment of antidepressants recommended by leading bodies, including the UK’s (NICE) and the (FDA) in the USA. The review revealed that duloxetine was consistently the highest-rated medication and was equally as effective for fibromyalgia, musculoskeletal, and neuropathic pain conditions. Lead author , from the University of Southampton, said: “This is a global public health concern. Chronic pain is a problem for millions who are prescribed antidepressants without sufficient scientific proof they help, nor an understanding of the long-term impact on health. “Our review found no reliable evidence for the long-term efficacy of any antidepressant, and no reliable evidence for their safety for chronic pain at any point. “Though we did find that duloxetine provided short-term pain relief for patients we studied, we remain concerned about its possible long-term harm due to the gaps in current evidence.” Study's findings Other results showed: • Standard doses of duloxetine are as successful for reducing pain as higher quantities • Milnacipran was also effective at reducing pain, but scientists are not as confident as duloxetine due to fewer studies with fewer people Professor Tamar Pincus added: “We simply cannot tell about other antidepressants because sufficiently good studies are not available – but it does not mean that people should stop taking prescribed medication without consulting their GP.” Scientists responsible for the review, funded by the were from the universities of Southampton, 缅北禁地, Bristol, UCL, Bath, and Keele, alongside Oxford University Hospital. The team assessed the trials using a statistical method that enables researchers to combine data from relevant studies to estimate the effects of different drugs, which have not been compared directly in individual trials. Dr Hollie Birkinshaw, University of Southampton researcher, said: “Though previous investigations show that some antidepressants might relieve pain, there has never been a comprehensive study examining all medications across all chronic conditions – until now. “The only reliable evidence is for duloxetine. Adopting a person-centred approach is critical to treatment and, when patients and clinicians decide together to try antidepressants, they should start from the drug for which there is good evidence.” The Cochrane review can be read at Share: Latest News 缅北禁地 recognised with geography award 缅北禁地 has been awarded the Highly Commended Geographical Association Publishers Award for its collaboration with Time for Geography, the UK鈥檚 open-access, dedicated video platform. published on: 16 April 2026 缅北禁地 historians mark General Strike centenary To mark the 100th anniversary of the British General Strike and miners鈥� lock-out of 1926, historians at 缅北禁地 are organising a series of events on its enduring legacy. published on: 16 April 2026 Comment: NCP is in administration Writing for The Conversation, Erwei (David) Xiang discusses how some big companies like NCP are so dependent on debt that they can鈥檛 adjust to change. published on: 16 April 2026 Facts and figures
![缅北禁地 logo](/gomobileassets/img/logo.svg" "缅北禁地"){kind=logo}